---
layout: default
title: Hymecromone
parent: 僅模型預測 (L5)
nav_order: 313
evidence_level: L5
indication_count: 10
---

# Hymecromone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Hymecromone: From Biliary Spasm to Diabetic Nephropathy

## One-Sentence Summary

Hymecromone (4-methylumbelliferone, 4-MU) is a coumarin-derivative choleretic/antispasmodic agent, historically used for managing biliary spasm.
The TxGNN model predicts it may be effective for **Diabetic Nephropathy**, but this ranks purely on model score —
**0 clinical trials** and **0 publications** currently support this specific link.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Biliary spasm (cholagogue/antispasmodic) — noted in supporting literature; no Saudi Arabia regulatory license record exists |
| Predicted New Indication | Diabetic Nephropathy |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data for hymecromone is not available in this evidence pack (marked as a High-severity data gap). However, literature collected elsewhere in this pack (in support of a different candidate indication) identifies hymecromone as a hyaluronan synthase (HAS) inhibitor: it suppresses hyaluronan (HA) synthesis, and HA accumulation is mechanistically tied to tissue fibrosis and inflammation in several organ systems.

Diabetic nephropathy involves progressive renal fibrosis and inflammatory HA deposition, so there is a plausible theoretical bridge from "HA synthesis inhibition" to "renal protection." That said, this bridge has not been tested for hymecromone specifically in diabetic nephropathy — the evidence pack's own rationale for this candidate explicitly flags the link as unverified extrapolation from TxGNN's score alone (rank 3116 of the model's output, score 0.9985), with zero dedicated trials or publications identified after targeted searches of ClinicalTrials.gov, ICTRP, and PubMed.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The diabetic nephropathy prediction is supported by TxGNN score alone (L5, S0) — no clinical trial, no publication, and no directly validated mechanistic study exist for this drug-indication pair. Combined with a Blocking data gap on TFDA/regulatory safety labeling, this candidate cannot yet enter safety pre-screening.

**To proceed, the following is needed:**
- TFDA/SFDA package insert (warnings, contraindications) — currently a Blocking gap (DG001)
- Confirmed mechanism of action data for hymecromone — currently a High-severity gap (DG002)
- Preclinical or clinical evidence directly linking hymecromone to diabetic nephropathy (current HA-inhibition rationale is indirect, drawn from an unrelated indication's literature)

**Note:** Among this drug's other predicted indications, **type 1 diabetes mellitus** (rank 8, score 99.54%) has notably stronger support — three preclinical/mechanistic studies (L4, S1, "Research Question") showing HA-synthesis inhibition restores immune tolerance in autoimmune insulitis. If prioritizing by evidence quality rather than raw TxGNN score, that candidate may warrant earlier follow-up than diabetic nephropathy.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

